New blood test for diagnosing liposarcomas
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
This study is testing a new blood test to see if it can help diagnose liposarcomas without the need for invasive biopsies.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 158 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Montpellier) |
| Trial ID | NCT04224064 on ClinicalTrials.gov |
What this trial studies
This project aims to identify a new non-invasive blood biomarker for diagnosing liposarcomas by measuring circulating serine levels. Currently, the gold standard for diagnosis involves detecting Mdm2 amplification through a tumor biopsy, which can be invasive and limited. The study will involve blood sampling from patients with localized and relapsed liposarcomas, as well as healthy subjects matched by age and sex. The goal is to improve diagnostic accuracy and reduce the need for invasive procedures.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with localized or relapsed well-differentiated or dedifferentiated liposarcomas.
Not a fit: Patients undergoing neo-adjuvant treatment for their cancer or those with psychiatric conditions preventing informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a less invasive method for diagnosing liposarcomas, leading to earlier and more accurate treatment.
How similar studies have performed: While the approach of using blood biomarkers for cancer diagnosis is gaining traction, this specific method for liposarcomas is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for LPS patients cohort: Men/women older than 18 years old, Surgery for : * Localized WD-LPS and DD-LPS, and/or * WD-LPS or DD-LPS local relapse, and/or * WD-LPS or DD-LPS distant relapse and/or * Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent Inclusion Criteria for healthy subjects cohort: Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort Exclusion Criteria: Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma. Pregnancy and/or feeding
Where this trial is running
Montpellier
- Institut du Cancer de Montpellier - Val d'Aurelle — Montpellier, France (Recruiting)
Study contacts
- Study coordinator: Jean-Pierre BLEUSE, MD
- Email: DRCI-icm105@icm.unicancer.fr
- Phone: 0467613102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.